{"publication_id":"9ff9a2ac-5a2c-4db3-8004-dff34731a3f4","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 23/29 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_2","claim":"Semaglutide 2.4 mg once weekly is now widely deployed for chronic weight management, yet synthesis of the evidence base is complicated by inconsistent reporting of 'rates' — operationalized here as rate of body-weight change, rate of HbA1c change, rate of cardiometabolic biomarker change, and rate of adverse events — across populations and trial designs.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_3","claim":"We conclude that the 2.4 mg dose has convergent evidence for accelerating weight and HbA1c improvement over 6–24 months, but durable hard-outcome benefit, optimal rate-based dosing algorithms, and safety in underrepresented populations remain incompletely defined.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_4","claim":"Evidence-abstraction note.** The 29 retained reference papers are not 29 independent primary clinical trials: 23 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 6 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_5","claim":"This synthesis evaluates evidence on semaglutide intervention semaglutide 2 4 mg rates across 29 included source papers and 2757 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_6","claim":"The corpus contains 6 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_7","claim":"The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_8","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_9","claim":"The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_10","claim":"Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_11","claim":"Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_12","claim":"The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_13","claim":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_14","claim":"The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_15","claim":"The background evidence for semaglutide intervention semaglutide 2 4 mg rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hamarsheh 2026, Buse 2025, Ganeshalingam 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_16","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_17","claim":"Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the cardiometabolic, dosing and pharmacokinetics, contextual adjacent evidence outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_18","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_19","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_20","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_21","claim":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_22","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, longevity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_23","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_24","claim":"Topic-fit rationale: Sources are retained only when they operationalize semaglutide intervention semaglutide 2 4 mg rates directly or provide adjacent/contextual boundary evidence for the same construct. 6/29 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Garvey 2022 (indirect; Cardiometabolic), Hamarsheh 2026 (direct; Cardiometabolic), Sillassen 2025 (review; Cardiometabolic), Buse 2025 (direct; Cardiometabolic), Ciudin 2026a (indirect; Cardiometabolic).","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_25","claim":"Source-scope annex note: Ganeshalingam 2026 (Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly), Cortes 2024 (Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial), Buse 2025 (Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial), Park 2025 (Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial) are retained only as non-topic/contextual annex evidence when the manifest keeps them for boundary context, and are not pooled as direct evidence for the target outcome or as support for the primary directional conclusion.","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_26","claim":"Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=22 (direction: mixed=6; negative=1; null=5; positive=1; unclear=9; directness: direct=5; indirect=7; review=10; sources: Arslanian 2025; Buse 2025; Chrzanowski 2026; Ciudin 2026a; Ciudin 2026b; Cortes 2024; Efficacy of Semaglutide S n.d.; Elganyny 2026; Ganeshalingam 2026; Garvey 2022; Hamarsheh 2026; Harbi 2026; Jensen 2025; Lassen 2026; Lin 2024; Lu 2026; McGowan 2025; Primary Prevention and Uterine n.d.; Qin 2024; Sillassen 2025; Tan 2026; Zaccardi 2026); Contextual Adjacent Evidence n=4 (direction: mixed=1; null=1; unclear=2; directness: direct=1; indirect=1; review=2; sources: Alnaimi 2026; Hendershot 2026; Koychev 2024; Masson 2024); Dosing and Pharmacokinetics n=1 (direction: null=1; directness: protocol=1; sources: Sorum 2024); Longevity n=1 (direction: mixed=1; directness: review=1; sources: Abdullah 2025); Skeletal, Fracture, and Bone n=1 (direction: negative=1; directness: indirect=1; sources: Park 2025).","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_27","claim":"| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_28","claim":"| Cardiometabolic | Arslanian 2025: Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.0001; source-level statistic reported |","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_29","claim":"| Cardiometabolic | Chrzanowski 2026: Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.001; source-level statistic reported |","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]},{"claim_id":"claim_30","claim":"| Cardiometabolic | Harbi 2026: Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=5 extracted claim(s); receipt-level direction is the coded finding |","candidate_sources":[{"source_id":"source_1","study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":"https://doi.org/10.1038/s41591-022-02026-4","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_2","study":"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials","doi":"10.1002/edm2.70248","url":"https://doi.org/10.1002/edm2.70248","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_3","study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","url":"https://doi.org/10.1186/s12916-025-04486-0","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level"},{"source_id":"source_4","study":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial","doi":"10.1136/bmjdrc-2025-005161","url":"https://doi.org/10.1136/bmjdrc-2025-005161","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"},{"source_id":"source_5","study":"Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity","doi":"10.1111/dom.70773","url":"https://doi.org/10.1111/dom.70773","support_kind":"candidate_source_row","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary"}]}]}